Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

por Bays, Harold E., Kozlovski, Plamen, Shao, Qing, Proot, Pieter, Keefe, Deborah
Publicado 2020

Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure

por de Boer, Rudolf A., Núñez, Julio, Kozlovski, Plamen, Wang, Yi, Proot, Pieter, Keefe, Deborah
Publicado 2020

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study

por Vencio, Sérgio, Manosalva, Juan P., Mathieu, Chantal, Proot, Pieter, Lozno, Hernan Yupanqui, Paldánius, Päivi M.
Publicado 2021

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM

por Matthews, David R., Paldánius, Päivi M., Stumvoll, Michael, Han, Jackie, Bader, Giovanni, Chiang, YannTong, Proot, Pieter, Del Prato, Stefano
Publicado 2019

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

por Yoo, Soon-Jib, Chang, Sang-Ah, Sohn, Tae Seo, Kwon, Hyuk-Sang, Lee, Jong Min, Moon, Sungdae, Proot, Pieter, Paldánius, Päivi M, Yoon, Kun Ho
Publicado 2021